SCIENTIFIC PEER REVIEW OF CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS’ RARE CANCERS RESEARCH PROGRAM FOR THE DEPARTMENT OF DEFENSE
The Congressionally Directed Medical Research Programs’ (CDMRP), Rare Cancers Research Program (RCRP) consumer advocate, Jeremy Kitzhaber, recently participated in the evaluation of research applications submitted to the RCRP. Jeremy Kitzhaber was nominated for participation in the program by the (ACPMP) Appendix Cancer Pseudomyxoma Peritonei Research Foundation. As a consumer reviewer, he was a full voting member, (along with prominent scientists) at meetings to help determine how the $7.5 million appropriated by Congress for Fiscal Year 2020 will be spent on RCRP research.
Consumer reviewers are asked to represent the collective view of patients by preparing comments on the impact of the research on issues such as diagnosis, treatment, and quality of life. When commenting on serving as a consumer reviewer, Jeremy Kitzhaber said that, “It was a very interesting, enlightening, and rewarding experience.”
The U.S. Congress established the Rare Cancers Research Program in the FY20 Department of Defense appropriation. With this new program, consumer advocates and scientists work together in this unique partnership to evaluate the scientific merit of research applications.
Scientists applying propose to greatly improve outcomes for people with rare cancers through discovery, community building, and expansion of knowledge across the cancer landscape.
Thank you Jeremy for your participation on the review panel for the RCRP program. We appreciate you representing our community in this important initiative!